The old cliché of “a game of two halves” can apply almost perfectly to Inovio Pharmaceuticals’ (INO) 2020. Until roughly the end of June, shares of the formerly little-known biotech were on an absolute tear. As one of the smaller companies to benefit from the market’s infatuation with “coronavirus stocks,” the company’s valuation soared on the premise of the successful development of INO-4800, its DNA COVID-19 vaccine candidate.But since then, sentiment has soured as the vaccine’s development has not gone smoothly. Progress hit a brick wall in September, when the FDA halted the planned Phase 2/3 study of INO-4800. The …read more
Source:: Yahoo Finance
